The effects of ketamine and esketamine on functional outcomes in major depressive disorder and treatment-resistant depression: A systematic review
PsiquiatriaResumo original em inglês
O que aconteceu
Functional impairment is commonly reported amongst individuals with major depressive disorder (MDD) or treatment-resistant depression (TRD). Extant evidence suggests that ketamine and esketamine, N-methyl-D-aspartate (NMDA) receptor antagonists and glutamatergic modulators, have shown efficacy in treating MDD/TRD. While symptom reduction remains central to treatment, many individuals with TRD continue to experience work, social and family difficulties even when mood symptoms remit. Hence, this review synthesizes evidence on the effect of es/ketamine on functional outcomes, as measured by workplace productivity and psychosocial function.
A systematic search was conducted in PubMed, OVID (Embase) and PsychInfo through February 1, 2025. Eligible studies were randomized controlled trials (RCTs) or post hoc RCT analyses in adults (≥18 years) with MDD or TRD, examining ketamine (R- or S-enantiomer, intravenous) or intranasal esketamine. Comparators included placebo, standard care, antidepressants or other active agents. Primary outcomes were functional impairment, workplace performance and related domains.
O que encontraram
No controlled studies were identified for ketamine, emphasizing a considerable gap in literature. Nine studies investigated esketamine and functional impairment. Significant mean [sd] reduction in Sheehan Disability Scale (SDS) scores were observed with esketamine (-13.6, [8.31]) versus placebo (-9.4, [8.43]). Workplace productivity also significantly improved; notably, reduced productivity loss (p = 0.0045), presenteeism (p = 0.0098), and activity impairment (p = 0.0172) relative to controls.
Por que isso importa
Esketamine alleviates depressive symptoms and improves functioning, notably in workplace domains. Future studies should include functional outcomes as key secondary or co-primary outcomes, reflecting the ultimate goal of recovery in TRD/MDD.
Resumo publicado sob licença CC BY. A tradução para o português ainda não chegou a este estudo.
O estudo original
The effects of ketamine and esketamine on functional outcomes in major depressive disorder and treatment-resistant depression: A systematic review
Isabella S Ji, Morgan C H Cheng, Kayla M Teopiz, Christine E Dri, Sabrina Wong, Gia Han Le, Taeho Greg Rhee, Hernan F Guillen-Burgos, Heidi K Y Lo, Yang Jing Zheng et al.
Descritores MeSH
- Ketamine
- Major Depressive Disorder
- Depressive Disorder, Treatment-Resistant
- Antidepressive Agents
- Outcome Assessment, Health Care
- Excitatory Amino Acid Antagonists
- Humans
Veja também
Estudos relacionados
- Intranasal esketamine for patients with major depressive disorder: A systematic review and meta-analysis
- Antidepressant efficacy of ketamine plus naltrexone for major depression comorbid with alcohol use disorder: a randomized controlled trial
- Acute subanesthetic ketamine-induced effects on the mismatch negativity and their relationship to early and sustained treatment response in major depressive disorder
- Efeitos cognitivos do tratamento com cetamina e esquetamina para a perturbação depressiva e bipolar major: uma revisão sistemática